ARTICLE | Clinical News
Therafab: Began Phase I trial
February 5, 2001 8:00 AM UTC
Antisoma plc (LSE:ASM; EASDAQ:ASOM), London, U.K. Product: Therafab Business: Cancer Therapeutic category: Antibody Target: Polymorphic epithelial mucin ( PEM), an abnormal form of mucin produced by ...